c-Met receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Émilie du Châtelet (1706–1749) proposed and tested the hypothesis of the conservation of total energy, as distinct from momentum. Inspired by the theories of Gottfried Leibniz, she repeated and publicized an experiment originally devised by Willem 's Gravesande in 1722 in which balls were dropped from different heights into a sheet of soft clay. Each ball's kinetic energy—as indicated by the quantity of material displaced—was shown to be proportional to the square of the velocity. The deformation of the clay was found to be directly proportional to the height from which the balls were dropped, equal to the initial potential energy. Some earlier workers, including Newton and Voltaire, had believed that "energy" was not distinct from momentum and therefore proportional to velocity. According to this understanding, the deformation of the clay should have been proportional to the square root of the height from which the balls were dropped. In classical physics, the correct formula is
James William Middleton (born 15 April 1987) is a British entrepreneur who is the younger brother of Catherine, Princess of Wales. Born in Reading, Berkshire, Middleton was educated at St Andrew's School, Pangbourne. He briefly attended the University of Edinburgh before dropping out and founding a cake-making business. Middleton began receiving media attention during his eldest sister's relationship with and subsequent marriage to Prince William. He is a mental health advocate and has spoken about his experiences with major depressive disorder. Middleton is also an ambassador for the Pets As Therapy charity.
=== Metabolic === In acute hyperglycemia, ketoacidosis may develop because decreased insulin levels increase the activity of hormone sensitive lipase. The degradation of triacylglycerides by hormone-sensitive lipase produces free fatty acids that are eventually converted to acetyl-coA by beta-oxidation. Ketoacidosis is a life-threatening condition which requires immediate treatment. Symptoms include: shortness of breath, breath that smells fruity (such as pear drops), nausea and vomiting, and very dry mouth. Another life-threatening consequence of hyperglycemia is nonketotic hyperosmolar syndrome.
== Museum history == The Arabia Steamboat Museum opened on November 13, 1991. Various elements of the museum operated under different corporations: Arabia Instructional Museum Society (1995-2004), Arabia Museum Foundation (founded 1990) and Arabia Salvage Ltd.(founded 1988). The museum and its operations were led by the two brothers who found and excavated the Arabia, Greg and David Hawley, and their parents, Bob and Florence Hawley. Greg was killed by a street racing driver in 2009. Bob died in 2019 and Florence died in 2021. David has continued the operation. The lease in Kansas City (7 miles from the Arabia wreck site) expires in 2026. Plans have been developed to move and expand the Arabia Steamboat Museum. In 2019, it was proposed to build the larger museum and move to Jefferson City, about 140 miles from the site of the Arabia wreck. In 2021, plans were made to create the National Steamboat Museum at Marshall Junction, Missouri, about 77 miles from the site of the wreck. The plans include excavating five additional steamboats so that six are interpreted and displayed at the museum. The Marshall-Saline Development Corporation advance funded a $150,000 feasibility study for the new museum, but is not raising or collecting funds for the museum. On November 13, 2025, the museum announced on their website that they would be closing permanently in November 2026.
== See also == List of supermarket chains, for supermarkets worldwide List of convenience shops in the United Kingdom List of discount shops in the United Kingdom List of clothing and footwear shops in the United Kingdom
Sources: en.wikipedia.org
=== Zinc(I) compounds === Zinc(I) compounds are very rare. The [Zn2]2+ ion is implicated by the formation of a yellow diamagnetic glass by dissolving metallic zinc in molten ZnCl2. The [Zn2]2+ core would be analogous to the [Hg2]2+ cation present in mercury(I) compounds. The diamagnetic nature of the ion confirms its dimeric structure. The first zinc(I) compound containing the Zn–Zn bond, (η5-C5Me5)2Zn2 has been reported in 2004.
In 1978, Vietnam invaded Kampuchea and captured Phnom Penh in January 1979, deposed the Maoist Khmer Rouge from government by the proclamation of the People's Republic of Kampuchea and established the Cambodia Liberation Front for National Renewal as the government of Cambodia, the Kampuchean People's Revolutionary Party (KPRP) also came to power in January 1979.
Galactose oxidase is a type II copper protein. It contains a single copper center that adopts square planar or square-based pyramidal coordination geometry. The copper center has five coordinating ligands: two tyrosines (Tyr272 and Tyr495), two histidines (His496 and His581), and a solvent molecule that is usually water. The copper in the active site of galactose oxidase is described as having a "distorted square pyramidal" coordination geometry. Tyr495 is the axial ligand, the other four ligands lie roughly in a plane. Both histidines coordinate with copper through 3-nitrogen. Copper-H2O bond is the longest coordinate bond; it is labile and can be replaced by a substrate molecule. Tyr272 forms a dimer with a cysteine (Cys228) through an ortho carbon of tyrosine and the sulfur atom of cysteine, which is supported by X-ray crystallography studies. The Tyr-Cys cross-link decreases the structural flexibility of Tyr272. This cross-linked tyrosinate is also a free radical. In the fully oxidized form of galactose oxidase, the free radical couples to the copper(II) center antiferromagnetically, supported by EPR spectroscopic studies. Moreover, the formation of cross-linking thioether bond is believed to lower the oxidation potential of Tyr272 phenoxide, making this phenoxyl more easily oxidized to form the radical in post-translational modification. The free radical in galactose oxidase is unusually stable compared to many other protein free radicals. The free radical ligand is stabilized mainly in two ways.
==== Federal regulation ==== In March 2016, OSHA mandated that companies must provide certain safety measures for employees who work with or around silica, in order to prevent silicosis, lung cancer, and other silica-related diseases. As part of the updated standard, OSHA created a table of engineering and administrative control methods to reduce silica exposure when using specific tools in 18 different applications that are known to create an exposure to silica. The key provisions of the updated standard include:
Sources: en.wikipedia.org
=== Personal objections === Sometimes people refuse blood transfusions because of fears about the safety of the blood supply. Generally speaking, the rules of informed consent allow mentally competent adults to refuse blood transfusions even when their objections are based on misinformation or prejudice and even when their refusal may result in serious and permanent harm, including death. For example, since COVID-19 vaccines became available, some people have refused blood transfusions because the donor might have been vaccinated, and they fear that this would cause secondhand harm to them. This choice is based on false beliefs, but a mentally competent adult's choices are normally respected. However, if doctor's opinions are that parents and guardians are making harmful choices about children, they can be overruled (in some jurisdictions) using legal arguments based on the harm principle; in this case if doctors believe that refusing the blood transfusion would put the child at risk of serious injury or death. Blood banks do not collect information that is irrelevant to the transfusion process, including the donors' race, ethnicity, sexual orientation, COVID-19 vaccination status, etc., so selecting blood units based on the individual's personal objections is not practical.
cisterna (pl.) cisternae Any of a class of flattened, membrane-bound vesicles or saccules of the smooth and rough endoplasmic reticulum and the Golgi apparatus. By traveling through one or more cisternae, each of which contains a distinct set of enzymes, newly created proteins and polysaccharides undergo chemical modifications such as phosphorylation and glycosylation, which are used as packaging signals to direct their transport to specific destinations within the cell.
== Role in evolution == By introducing novel genetic qualities to a population of organisms, de novo mutations play a critical role in the combined forces of evolutionary change. However, the weight of genetic diversity generated by mutational change is often considered a generally "weak" evolutionary force. Although the random emergence of mutations alone provides the basis for genetic variation across all organic life, this force must be taken in consideration alongside all evolutionary forces at play. Spontaneous de novo mutations as cataclysmic events of speciation depend on factors introduced by natural selection, genetic flow, and genetic drift. For example, smaller populations with heavy mutational input (high rates of mutation) are prone to increases of genetic variation which lead to speciation in future generations. In contrast, larger populations tend to see lesser effects of newly introduced mutated traits. In these conditions, selective forces diminish the frequency of mutated alleles, which are most often deleterious, over time.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.